跳至主要内容
临床试验/CTIS2024-513890-30-00
CTIS2024-513890-30-00进行中(未招募)1 期

SePkLin Study: Pragmatic, Multicenter, Randomized, Controlled Clinical Trial in Patients with Sepsis to Evaluate the Safety and Efficacy of Personalized Pk/Pd Dosing Versus Standard Dosing of LINezolid. - SePkLI

Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela0 个研究点目标入组 692 人开始时间: 2024年7月23日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
692

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Adult patients (18 years and older) receiving linezolid., Diagnosis of sepsis (SOFA scale = 2 points or in the case of chronic organ dysfunction, increase of 2 points compared to the baseline score)., Patients have started antibiotic treatment with linezolid according to usual clinical practice.

排除标准

  • Interruption of treatment before the first blood sample., Pregnant or nursing women., Known allergy or hypersensitivity to linezolid., Patients will be excluded if they are already in any other intervention trials.

研究者

相似试验

SePkLin Study: Pragmatic, Multicenter, Randomized,... | 临床试验